Filing Details
- Accession Number:
- 0001610717-24-000516
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-04 16:05:32
- Reporting Period:
- 2024-10-31
- Accepted Time:
- 2024-11-04 16:05:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1628171 | Revolution Medicines Inc. | RVMD | Biological Products, (No Disgnostic Substances) (2836) | 472029180 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1860609 | Sushil Patel | C/O Revolution Medicines, Inc. 700 Saginaw Dr Redwood City CA 94063 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-10-31 | 5,000 | $24.84 | 24,948 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-31 | 5,000 | $54.14 | 19,948 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-31 | 5,000 | $0.00 | 5,000 | $24.84 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 13,400 | 2024-06-08 | 2033-06-07 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023.
- Includes 7,748 restricted stock units.
- The transaction was executed in multiple trades in prices ranging from $54.00 to $54.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
